- Recent Funding
- Founders
- Viswa Colluru
About Viswa
Viswa Colluru is the Founder and CEO of Enveda, a biotechnology company that uses AI to discover new drugs from natural sources. He founded Enveda in 2019 with the goal of accelerating the discovery of better medicines by learning from life's chemistry. Enveda's approach involves using AI-powered tools to identify and characterize molecules from living organisms, with several drug candidates currently in clinical trials for conditions like atopic dermatitis, asthma, obesity, and inflammatory bowel disease.
Strengths: founder archetype
one sourced signal · hover a cell for it, click for the source
Why technical builder
Viswa Colluru's background includes a PhD and a focus on solving hard problems, indicating a strong technical and research foundation. He then applied this expertise to build Enveda, a company that leverages AI and natural chemistry for drug discovery, demonstrating his operational capabilities within a specific domain.
The signals behind it 5
- India ‣ US for PhD @UWMadisonResearcher · Technical builderX
- Love solving hard problems with amazing peopleTechnical builderX
- I started @enveda so mothers could fight their diagnoses with power mine never had.Domain operatorX
- Enveda’s mission is simple: Turn life’s chemistry into hope — for the people we love.Domain operatorX
- Viswa Colluru, an early employee of Recursion Pharmaceuticals, founded Enveda in 2019 to speed up the process of discovering these new drugs using AI and other techniques.Technical builder · Domain operatorT
Viswa Colluru | From PhD to AI Drug Discovery Founder
Every tag links its source.
Network
Timeline, line by line 8
- Enveda raised $311M (Series B+), led by Catalio.Sep 23, 2026
F - Announced $150M Series D funding for EnvedaSep 4, 2025X
- Welcomed Mikael Dolsten to Enveda's boardSep 4, 2025X
- F
- F
- Enveda raised $55M (Series B+).Jun 14, 2024T
E- Founded Enveda2019
T
In their words
7
- “I started @enveda so mothers could fight their diagnoses with power mine never had.”Explaining the personal motivation behind founding Enveda. · Sep 23, 2026X
- “Pharma spent 30 years going biology-first. Enveda is built on the opposite bet.”Describing Enveda's unique chemistry-first approach to drug discovery. · Apr 22, 2026X
- “More than a drug, it’s proof that the system we built works. ENV-294 is the moment where promise becomes proof!”Highlighting the significance of ENV-294's clinical data as validation for Enveda's platform. · Jan 10, 2026X
- “Enveda’s mission is simple: Turn life’s chemistry into hope — for the people we love.”Stating Enveda's core mission. · Jun 17, 2025X
- “Asthma is close to my heart. It can be debilitating and scary — especially if your inhaler isn’t nearby. We’re incredibly excited about the potential for ENV-294 to offer a non-steroidal oral option for long-term use!”Expressing personal connection and excitement for ENV-294's potential in asthma treatment. · Feb 5, 2025X
- “There’s a grammar to Mother Nature. Across Chemistry and Biology, there’s a new era of reading, understanding, and writing.”Discussing the potential of AI and LLMs to decode natural chemistry. · Oct 27, 2023X
- “At @envedabio, we bet on the enduring wisdom of the ages to reliably guide our Platform”Explaining Enveda's reliance on natural products and ethnobotany. · Oct 6, 2023X
Interviews and coverage
7
- Enveda, an AI drugmaker, banks $311M in venture fundingBioPharma Dive · Sep 23, 2026
B - Inspired by Mother Nature, Discovering New Drugs: Viswa Colluru on The Long RunTimmerman Report · Mar 31, 2026T
- Enveda CEO Viswa Colluru on AI and biotech: 'we're at a unique moment in time'qz.com · Aug 6, 2026
Q - Enveda raises its third megaround in as many years for I&I and weight maintenance drug candidatesEndpoints News · Sep 23, 2026
E - Enveda Reports Positive Results for ENV-294 in a Phase 1b Clinical Trial of Patients with Moderate-to-Severe Atopic DermatitisBioSpace · Mar 31, 2026
B - Enveda secures $311M to bring more nature-derived AI drugs into clinical trialsTechCrunch · Sep 23, 2026T
- Enveda Secures $150M in Series D Funding, Enrolls First Patient in Lead Program, Welcomes Mikael Dolsten to BoardSynBioBeta · Sep 9, 2025
S
How this is researched
Researched from public pages: press, interviews, the company's site and the founder's own posts. Each source logo links the page that states the row; anything we couldn't source is left out. The archetype is our reading of that record, from a fixed set so founders can be compared. Updated Oct 12, 2026.
The week's top funded startups and market insights, in your inbox every Monday.
Unsubscribe anytime · privacy